Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment

被引：119

作者：

Stein, RC

机构：

[1] UCL Royal Free & UCL Med Sch, Ludwig Inst Canc Res, London W1W 7BS, England

[2] UCL Royal Free & UCL Med Sch, Dept Oncol, London W1W 7BS, England

来源：

ENDOCRINE-RELATED CANCER | 2001年 / 8卷 / 03期

关键词：

D O I：

10.1677/erc.0.0080237

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The phosphoinositide 3-kinases (PI3-kinases) are a family of lipid kinases that have a key role in the regulation of many cellular processes including proliferation, survival, carbohydrate metabolism, and motility. There is now strong evidence that some members of the PI3-kinase family have an important role in cancer. Emerging evidence for functional specialisation of PI3-kinase isoforms suggests that isoform selective inhibitors, in contrast to the existing non-selective inhibitors wortmannin and LY294002, may prove to be useful anticancer drugs.

引用

收藏

页码：237 / 248

页数：12

相关论文

共 65 条

[1] Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity [J].

Ali, IU ;

Schriml, LM ;

Dean, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (22) :1922-1932

[2] A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt [J].

Aoki, M ;

Blazek, E ;

Vogt, PK .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (01) :136-141

[3] The catalytic subunit of phosphoinositide 3-kinase: Requirements for oncogenicity [J].

Aoki, M ;

Schetter, C ;

Himly, M ;

Batista, O ;

Chang, HW ;

Vogt, PK .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (09) :6267-6275

[4] Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors [J].

Arcaro, A ;

Zvelebil, MJ ;

Wallasch, C ;

Ullrich, A ;

Waterfield, MD ;

Domin, J .

MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (11) :3817-3830

[5] Enhanced phosphorylation of p53 by ATN in response to DNA damage [J].

Banin, S ;

Moyal, L ;

Shieh, SY ;

Taya, Y ;

Anderson, CW ;

Chessa, L ;

Smorodinsky, NI ;

Prives, C ;

Reiss, Y ;

Shiloh, Y ;

Ziv, Y .

SCIENCE, 1998, 281 (5383) :1674-1677

[6] MOLECULAR ALTERATIONS OF THE AKT2 ONCOGENE IN OVARIAN AND BREAST CARCINOMAS [J].

BELLACOSA, A ;

DEFEO, D ;

GODWIN, AK ;

BELL, DW ;

CHENG, JQ ;

ALTOMARE, DA ;

WAN, MH ;

DUBEAU, L ;

SCAMBIA, G ;

MASCIULLO, V ;

FERRANDINA, G ;

PANICI, PB ;

MANCUSO, S ;

NERI, G ;

TESTA, JR .

INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (04) :280-285

[7] Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase [J].

Bi, L ;

Okabe, I ;

Bernard, DJ ;

Wynshaw-Boris, A ;

Nussbaum, RL .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (16) :10963-10968

[8]

Borlado LR, 2000, FASEB J, V14, P895

[9] Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002 [J].

Brunn, GJ ;

Williams, J ;

Sabers, C ;

Wiederrecht, G ;

Lawrence, JC ;

Abraham, RT .

EMBO JOURNAL, 1996, 15 (19) :5256-5267

[10] Phosphatidylinositol-3-OH kinases are Rab5 effectors [J].

Christoforidis, S ;

Miaczynska, M ;

Ashman, K ;

Wilm, M ;

Zhao, LY ;

Yip, SC ;

Waterfield, MD ;

Backer, JM ;

Zerial, M .

NATURE CELL BIOLOGY, 1999, 1 (04) :249-252

← 1 2 3 4 5 6 7 →